Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 3/20 | 0.87 |
| ▸ | EGFR | P00533 | 7/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | BTK | Q06187 | 6/20 | 0.61 |
| ▸ | JAK2 | O60674 | 4/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 7/20 | 0.57 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | BLK | P51451 | 1/20 | 0.53 |
| ▸ | BMX | P51813 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16514480 | 0.94 | FGFR2 (0.84) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL29847948 | 0.94 | FGFR2 (0.84) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL16513666 | 0.93 | FGFR2 (1.00) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL29847475 | 0.92 | FGFR2 (0.87) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL16513498 | 0.92 | FGFR2 (0.87) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL16515126 | 0.92 | FGFR2 (0.83) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL20787702 | 0.91 | FGFR2 (0.85) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL16514922 | 0.91 | EGFR (0.85) | FGFR2EGFRFGFR1KDRBTK | |
| SCHEMBL29847016 | 0.91 | EGFR (0.85) | FGFR2EGFRFGFR1KDRBTK | |
| Hydrochloric Acid SCHEMBL16513760 | 0.91 | EGFR (0.84) | FGFR2EGFRFGFR1KDRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306259-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2020-10-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306259-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | FGFR2 1364/4885EGFR 518/4885FGFR1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.